Soleus Capital Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Soleus Capital Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7,300	Closed	-$1.65M	–	94
2022 Q3	$1.65M	Sell	7,300 -20,900	-74%	-$5.14M	0.22%	59
2022 Q2	$5.33M	Buy	28,200 +2,100	+8%	+$423K	0.83%	37
2022 Q1	$6.5M	Buy	+26,100	New	+$4.13M	0.84%	36
2021 Q4	–	Sell	-7,117	Closed	-$1.43M	–	89
2021 Q3	$1.43M	Hold	7,117	–	–	0.22%	61
2021 Q2	$1.82M	Hold	7,117	–	–	0.28%	53
2021 Q1	$1.89M	Buy	7,117 +926	+15%	+$292K	0.34%	52
2020 Q4	$2.28M	Sell	6,191 -9,561	-61%	-$2.74M	0.3%	37
2020 Q3	$3.85M	Sell	15,752 -4,924	-24%	-$1.53M	2.04%	20
2020 Q2	$5.95M	Buy	20,676 +7,169	+53%	+$2.11M	3.39%	8
2020 Q1	$2.75M	Buy	13,507 +6,660	+97%	+$2.12M	3.21%	11
2019 Q4	$3.06M	Buy	+6,847	New	+$2.43M	2.95%	13

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Soleus Capital Management's EIGR Position: Q4 2022 in Review

Soleus Capital Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2022, closing a stake of 7,300 shares — an estimated $1.65M sold.

Soleus Capital Management first reported a position in EIGR in Q4 2019 and held it in 11 quarters. The position peaked at $6.5M in Q1 2022. 81 funds tracked by Wall St. Rank hold EIGR as of Q4 2022.

Soleus Capital Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
Soleus Capital Management sold 7,300 Eiger BioPharmaceuticals, Inc. shares in Q4 2022, an estimated $1.65M.
Soleus Capital Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2019 and held it in 11 quarters.
Soleus Capital Management's Eiger BioPharmaceuticals, Inc. position peaked at $6.5M in Q1 2022.
81 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2022.

Based on Soleus Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.